It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
We are experts in small molecule drug discovery, spanning target ID to candidate validation and scale up. With over 20 years of experience, our multi-disciplinary teams have forged strong partnerships with our customers, delivering over 60 candidates and tackling even the most difficult targets.
We know what a good small molecule looks like. Even at the early stages of drug discovery we’re thinking about what the final product needs to be and then we work backwards to plan for your success.
Our teams are proven at finding chemical starting points for difficult targets and are experienced in navigating complex IP landscapes. Great early-stage science is key, as problems only become amplified as you go through the process.
We’re problem solving, across biology, chemistry, comp chem & DMPK, throughout the discovery process. We’re always asking questions: if we really have the right chemical starting points; what is the data telling us; and what are the best decisions we can take at this stage in the process? Sometimes it’s best to stop and reallocate resources to programs with better chances of success.
Whether we’re supporting you through the entire process or just a part of it, our goal isn’t simply to move you to the next stage, it’s to lay the foundations for a successfully marketed drug.
Our solutions
We have decades of small molecule drug discovery experience, from target ID to candidate selection and scale up. But whatever the stage we’re working on, our aim is to produce molecules that make it all the way to the market.
Target ID & Validation
How druggable is your target? What will lead to the best efficacy? We’re not just identifying and validating your target but validating the mechanism you’re using to hit it. Ideally this is done in advance of hit finding so that the techniques used can be aligned with the mechanism.
The more options, the better the chances of success. We’re looking for diversity, ideally using multiple hit-finding techniques and are already asking: is this class of compound going to make it to market?
Here we really explore chemical space, making molecules quickly that are relatively diverse. At the end of hit to lead, molecules should have significant potency in in vitro systems and there should be an understanding of the challenges we’re likely to face in lead optimization.
A combination of AI models and human experience really come into their own now. It’s about fine tuning & understanding which series is most likely to make it all the way. Dose prediction is top of mind in order that we can deliver compounds with the best chance of clinical success.
A combination of AI models and human experience really come into their own now. It’s about fine tuning & understanding which series is most likely to make it all the way. Dose prediction is top of mind in order that we can deliver compounds with the best chance of clinical success.
Scale Up & Formulation
The FDA cited that 60% of drugs are delayed getting to the marketplace due to sub-standard processes and manufacturing, and last-minute changes are costly. Therefore, having the right processes agreed preclinically, will enhance both the program ’s cost effectiveness and chances of success.
Small molecule landscape
Despite the popularity of many new modalities, small molecules remain the largest segment of the market. For all the reasons we know in terms of cost of goods, ease of use and their ability to reach parts of the body that other modalities may struggle to reach e.g. CNS.
Small molecules account for ~80% of all FDA -approved drugs, with 64% of new drug approvals being small molecules (in 2024).
Global small molecule drug market projected to exceed US$58 billion by 2030 (CAGR ~5%)
Rapid growth in AI -assisted chemistry, computer aided drug design (CADD) and structure -based design (SBD).
Case Studies
Trusted by customers worldwide
Our customers tell us that we act as an extension of their team and provide high quality expertise at every stage of the drug discovery process. Whether we’re supporting you through the entire process, or just a part of it, our goal isn’t simply to move you to the next stage it’s to lay the foundations for a successfully marketed drug.
From Lead to Pre-Candidate Nomination in 18 Months
Progressing from lead to pre candidate nomination in less than half the industry standard timeline, this program shows how connected scientific teams and real time insight can accelerate complex discovery.
Many intriguing drug discovery programmes begin life at start-up biotech companies. Yet at the outset, these new organisations rarely have the resources or laboratory set-up immediately available to turn their ground-breaking ideas into a new medicine.
Rapid creation of ideas using generative AI (GenAI) with Iktos Makya
Leading generative artificial intelligence (GenAI) algorithms for de novo design are being used routinely within our medicinal chemistry programmes to enable rapid idea generation to address project objectives.
Fragment-based hit discovery for the epigenetic target, BRD3
Fragment-based drug discovery allows a wide section of chemical space to be interrogated with a relatively small but diverse library of small molecules.
Insights from Dr. Allan Jordan, Sygnature’s VP of Oncology Drug Discovery into the reasons behind the struggles faced by inhibitors targeting IDO, TDO, and A2a receptors, and discover potential avenues for renewed hope, including agonists of the STING pathway and inhibitors of HPK-1 and Cbl-B.
Over the last decade, GLP-1 therapies have transformed diabetes and obesity treatment. Discover the potential of small molecules in this field and their role in revolutionizing treatment options and improving patient outcomes.
Sitryx Therapeutics selects Sygnature Discovery for multi-target, integrated drug discovery collaboration. The energetic status of…
News
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Delivering validated, high-quality hits through integrated technologies, strategic insight, and expert collaboration to advance your program with confidence.
Transforming early leads into clinical-quality candidates through integrated expertise, rapid decision-making, and optimized strategies for safety, potency, and exposure.
Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.
Automated high-throughput chemistry delivering rapid, high-quality compound libraries enabling efficient SAR exploration and faster progression from concept to candidate.
